These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36536048)

  • 41. Early detection, PSA screening, and management of overdiagnosis.
    Borza T; Konijeti R; Kibel AS
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1091-110, vii. PubMed ID: 24188254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model.
    Nordström T; Grönberg H; Adolfsson J; Egevad L; Aly M; Eklund M
    Eur Urol Focus; 2018 Apr; 4(3):385-387. PubMed ID: 28753831
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prostate cancer screening: Reasons of controversy].
    Delporte G; Villers A; Penel N
    Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overdiagnosis in early detection programs.
    Davidov O; Zelen M
    Biostatistics; 2004 Oct; 5(4):603-13. PubMed ID: 15475422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prostate cancer screening - past, present, future].
    Szalontai J; Horváth A; Szűcs M; Nyirády P
    Magy Onkol; 2022 Oct; 66(3):219-222. PubMed ID: 36200502
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.
    Morgan T; Palapattu G; Wei J
    Curr Urol Rep; 2015 Sep; 16(9):63. PubMed ID: 26169584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk-based prostate cancer screening: who and how?
    Glass AS; Cary KC; Cooperberg MR
    Curr Urol Rep; 2013 Jun; 14(3):192-8. PubMed ID: 23532499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Too Much Healthcare: The Harmful Combination of Overdiagnosis and Medical Overuse, Told and Untold Stories.
    Gaver A
    Isr Med Assoc J; 2022 Jun; 24(6):399-402. PubMed ID: 35734840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systematic evaluation of written health information on PSA based screening in Germany.
    Beck S; Borutta B; Walter U; Dreier M
    PLoS One; 2019; 14(8):e0220745. PubMed ID: 31393928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Overdiagnosis in cancer screening].
    Cervera Deval J; Sentís Crivillé M; Zulueta JJ
    Radiologia; 2015; 57(3):188-92. PubMed ID: 25174786
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conceptualizing overdiagnosis in cancer screening.
    Marcus PM; Prorok PC; Miller AB; DeVoto EJ; Kramer BS
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25663695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
    Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
    JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preventing prostate cancer overdiagnosis from becoming overtreatment.
    Hayes J; Barry MJ
    Oncology (Williston Park); 2011 May; 25(6):468, 471, 478. PubMed ID: 21717900
    [No Abstract]   [Full Text] [Related]  

  • 54. Pathology consultation on prostate-specific antigen testing.
    Noguez JH; Fantz CR
    Am J Clin Pathol; 2014 Jul; 142(1):7-15. PubMed ID: 24926079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Addressing overtreatment following the diagnosis of localized prostate cancer.
    Tawadros T; Valerio M
    Expert Rev Anticancer Ther; 2016; 16(4):373-4. PubMed ID: 26776104
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
    Gulati R; Gore JL; Etzioni R
    Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Solving the overdiagnosis dilemma.
    Esserman L; Thompson I
    J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743
    [No Abstract]   [Full Text] [Related]  

  • 58. Overdiagnosis in cancer.
    Welch HG; Black WC
    J Natl Cancer Inst; 2010 May; 102(9):605-13. PubMed ID: 20413742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Screening for prostate cancer: clinical significance and future perspectives].
    Ito K; Suzuki K
    Nihon Rinsho; 2016 Jan; 74(1):72-8. PubMed ID: 26793883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.
    Etzioni R; Gulati R; Mallinger L; Mandelblatt J
    Ann Intern Med; 2013 Jun; 158(11):831-8. PubMed ID: 23732716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.